Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Rev Clin Esp (Barc) ; 217(8): 473-477, 2017 Nov.
Article in English, Spanish | MEDLINE | ID: mdl-28318520

ABSTRACT

Non insulin antidiabetic drugs are widely used in patients with type 2 diabetes. However, the drugs' effect in terms of reducing cardiovascular risk has been the subject of controversy. In 2008, based on the evidence of cardiovascular risk resulting from the use of a number of non insulin antidiabetic drugs, the US Food and Drug Administration published directives on the need to perform cardiovascular safety studies. These directives have helped obtain more evidence, such that at present there are 2 families of drugs that can reduce cardiovascular risk. These recent data have helped us add the reduction of cardiovascular morbidity and mortality to the objective of controlling blood glucose. Nevertheless, research continues with the development of new long-term studies.

2.
Pediatr. aten. prim ; 19(73): e1-e25, ene.-mar. 2017. tab, graf, ilus
Article in Spanish | IBECS | ID: ibc-161853

ABSTRACT

Las VI Guías Europeas de Prevención Cardiovascular recomiendan combinar las estrategias poblacional y de alto riesgo, con los cambios de estilo de vida como piedra angular de la prevención, y proponen la función SCORE para cuantificar el riesgo cardiovascular. Esta guía hace más hincapié en las intervenciones específicas de las enfermedades y las condiciones propias de las mujeres, las personas jóvenes y las minorías étnicas. No se recomienda el cribado de aterosclerosis subclínica con técnicas de imagen no invasivas. La guía establece cuatro niveles de riesgo (muy alto, alto, moderado y bajo), con objetivos terapéuticos de control lipídico según el riesgo. La diabetes mellitus confiere un riesgo alto, excepto en sujetos con diabetes tipo 2 con menos de diez años de evolución, sin otros factores de riesgo ni complicaciones, o con diabetes tipo 1 de corta evolución sin complicaciones. La decisión de iniciar el tratamiento farmacológico de la hipertensión arterial dependerá del nivel de presión arterial y del riesgo cardiovascular, teniendo en cuenta la lesión de órganos diana. Siguen sin recomendarse los fármacos antiplaquetarios en prevención primaria por el riesgo de sangrado. La baja adherencia al tratamiento exige simplificar el régimen terapéutico e identificar y combatir sus causas. La guía destaca que los profesionales de la salud pueden ejercer un papel importante en la promoción de intervenciones poblacionales y propone medidas eficaces, tanto a nivel individual como poblacional, para promover una dieta saludable, la práctica de actividad física, el abandono del tabaquismo y la protección contra el abuso de alcohol (AU)


The VI European Guidelines for Cardiovascular Prevention recommend combining population and high-risk strategies with lifestyle changes as a cornerstone of prevention, and propose the SCORE function to quantify cardiovascular risk. The guidelines highlight disease specific interventions, and conditions specific to women, young people and ethnic minorities. Screening for subclinical atherosclerosis with noninvasive imaging techniques is not recommended. The guidelines distinguish four risk levels (very high, high, moderate and low) with therapeutic objectives for lipid control according to risk. Diabetes mellitus confers a high risk, except for subjects with type 2 diabetes with less than ten years of evolution, with no other risk factors or complications, or type 1 diabetes of short evolution without complications. The decision to start pharmacological treatment of arterial hypertension will depend on the blood pressure level and cardiovascular risk, taking into account the lesion of target organs. The guidelines do not recommend antiplatelet drugs in primary prevention because of the increased risk of bleeding. The low adherence to the medication requires simplified therapeutic regimes and identifying and combating its causes. The guidelines highlight the responsibility of health professionals to play an active role in promoting evidence-based interventions at the population level, and propose effective interventions, both at individual and population level, to promote a healthy diet, the practice of physical activity, the cessation of smoking and the protection against alcohol abuse (AU)


Subject(s)
Humans , Male , Female , Cardiovascular Diseases/prevention & control , Life Style , Risk Factors , Alcoholism/prevention & control , Smoking/prevention & control , Diabetes Mellitus/prevention & control , Hypertension/prevention & control , Trans Fatty Acids/administration & dosage , Indicators of Morbidity and Mortality , Arterial Pressure/physiology , Cholesterol/physiology , Biomarkers/analysis , Sedentary Behavior , Motor Activity
3.
Clin Investig Arterioscler ; 29(2): 69-85, 2017.
Article in English, Spanish | MEDLINE | ID: mdl-28173956

ABSTRACT

The VI European Guidelines for Cardiovascular Prevention recommend combining population and high-risk strategies with lifestyle changes as a cornerstone of prevention, and propose the SCORE function to quantify cardiovascular risk. The guidelines highlight disease specific interventions, and conditions as women, young people and ethnic minorities. Screening for subclinical atherosclerosis with noninvasive imaging techniques is not recommended. The guidelines distinguish four risk levels (very high, high, moderate and low) with therapeutic objectives for lipid control according to risk. Diabetes mellitus confers a high risk, except for subjects with type 2 diabetes with less than <10 years of evolution, without other risk factors or complications, or type 1 diabetes of short evolution without complications. The decision to start pharmacological treatment of arterial hypertension will depend on the blood pressure level and the cardiovascular risk, taking into account the lesion of target organs. The guidelines don't recommend antiplatelet drugs in primary prevention because of the increased bleeding risk. The low adherence to the medication requires simplified therapeutic regimes and to identify and combat its causes. The guidelines highlight the responsibility of health professionals to take an active role in advocating evidence-based interventions at the population level, and propose effective interventions, at individual and population level, to promote a healthy diet, the practice of physical activity, the cessation of smoking and the protection against alcohol abuse.


Subject(s)
Cardiovascular Diseases/prevention & control , Life Style , Practice Guidelines as Topic , Cardiovascular Diseases/etiology , Europe , Health Personnel/organization & administration , Humans , Medication Adherence , Professional Role , Risk Factors , Spain
4.
Hipertens Riesgo Vasc ; 34(1): 24-40, 2017.
Article in Spanish | MEDLINE | ID: mdl-28017552

ABSTRACT

The VI European Guidelines for Cardiovascular Prevention recommend combining population and high-risk strategies with lifestyle changes as a cornerstone of prevention, and propose the SCORE function to quantify cardiovascular risk. The guidelines highlight disease specific interventions, and conditions as women, young people and ethnic minorities. Screening for subclinical atherosclerosis with noninvasive imaging techniques is not recommended. The guidelines distinguish four risk levels (very high, high, moderate and low) with therapeutic objectives for lipid control according to risk. Diabetes mellitus confers a high risk, except for subjects with type 2 diabetes with less than <10 years of evolution, without other risk factors or complications, or type 1 diabetes of short evolution without complications. The decision to start pharmacological treatment of arterial hypertension will depend on the blood pressure level and the cardiovascular risk, taking into account the lesion of target organs. The guidelines don't recommend antiplatelet drugs in primary prevention because of the increased bleeding risk. The low adherence to the medication requires simplified therapeutic regimes and to identify and combat its causes. The guidelines highlight the responsibility of health professionals to take an active role in advocating evidence-based interventions at the population level, and propose effective interventions, at individual and population level, to promote a healthy diet, the practice of physical activity, the cessation of smoking and the protection against alcohol abuse.


Subject(s)
Cardiovascular Diseases/prevention & control , Practice Guidelines as Topic , Adult , Aged , Alcohol Drinking , Biomarkers , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/epidemiology , Comorbidity , Diabetes Mellitus/epidemiology , Diet , Dyslipidemias/epidemiology , Dyslipidemias/therapy , Early Diagnosis , Europe , Exercise , Female , Health Promotion , Humans , Life Style , Male , Middle Aged , Mortality/trends , Obesity/epidemiology , Risk Assessment , Smoking Cessation , Spain/epidemiology , Translations
5.
Neurologia ; 31(3): 195-207, 2016 Apr.
Article in English, Spanish | MEDLINE | ID: mdl-23969295

ABSTRACT

Based on the two main frameworks for evaluating scientific evidence (SEC and GRADE) European cardiovascular prevention guidelines recommend interventions across all life stages using a combination of population-based and high-risk strategies with diet as the cornerstone of prevention. The evaluation of cardiovascular risk (CVR) incorporates HDL levels and psychosocial factors, a very high risk category, and the concept of age-risk. They also recommend cognitive-behavioural methods (e.g., motivational interviewing, psychological interventions) led by health professionals and with the participation of the patient's family, to counterbalance psychosocial stress and reduce CVR through the institution of positive habits such as a healthy diet, physical activity, smoking cessation, and adherence to treatment. Additionally, public health interventions - such as smoking ban in public areas or the elimination of trans fatty acids from the food chain - are also essential. Other innovations include abandoning antiplatelet therapy in primary prevention and the recommendation of maintaining blood pressure within the 130-139/80-85 mmHg range in diabetic patients and individuals with high CVR. Finally, due to the significant impact on patient progress and medical costs, special emphasis is given to the low therapeutic adherence levels observed. In sum, improving cardiovascular prevention requires a true partnership among the political class, public administrations, scientific and professional associations, health foundations, consumer associations, patients and their families. Such partnership would promote population-based and individual strategies by taking advantage of the broad spectrum of scientific evidence available, from clinical trials to observational studies and mathematical models to evaluate population-based interventions, including cost-effectiveness analyses.


Subject(s)
Cardiovascular Diseases/prevention & control , Aging , Health Promotion , Humans , Preventive Medicine , Primary Prevention , Risk Assessment , Risk Management , Spain
6.
Rev Clin Esp (Barc) ; 213(3): 138-44, 2013 Apr.
Article in English, Spanish | MEDLINE | ID: mdl-22981073

ABSTRACT

BACKGROUND AND OBJECTIVE: Public administrations have to procure equitable care that compensates resistance factors such as communication problems and those arising from aging. Our objective was to analyze the influence of population dispersion and aging on the frequency rate of some common surgical procedures in elderly patients. PATIENTS AND METHODS: We used the database of surgical activity of the only hospital in a Spanish province to identify cataract surgeries, hip replacements and pacemaker implants performed during 2010. Using the National Statistics Institute Census, we calculated the rate for each procedure and the proportion of inhabitants over 65 in each municipality. Time needed to access the hospital by road from each municipality was used as a measure of dispersion. RESULTS: The population was distributed into 339 population centers, 90% of which had less than 1,000 inhabitants. The worst communicated populations were smaller (r=-0.194; P<.0001) and had a higher proportion of elderly (r=0.406; P<.0001). No relationship was found between the frequentation of the selected interventions and the number of inhabitants or travel time. Similarly, no differences were found when the analysis was done by pooling the population for 30 minutes isochrones. The percentage of those over 65 years was independently associated to the frequency rate of cataract surgery (beta=0.211; P<.001) and showed a trend to increased frequency for the implantation of pacemakers and hip replacements. CONCLUSIONS: Our study shows that, with the current organization of care and in the territory analyzed, neither population dispersion nor aging seems to reduce frequentation of several interventions typical of the elderly population.


Subject(s)
Arthroplasty, Replacement, Hip/statistics & numerical data , Cataract Extraction/statistics & numerical data , Health Services Accessibility/statistics & numerical data , Pacemaker, Artificial/statistics & numerical data , Age Factors , Aged , Aged, 80 and over , Demography , Female , Humans , Linear Models , Male , Spain
SELECTION OF CITATIONS
SEARCH DETAIL
...